Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie A Zorn

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Nature Chemical Biology|February 16, 2010
Turning enzymes ON with small moleculesJulie A Zorn, James A Wells
Methods in Enzymology|November 18, 2014
A structural atlas of kinases inhibited by clinically approved drugsQi Wang, Julie A Zorn, John Kuriyan
Plos One|April 4, 2015
Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)Julie A Zorn, Qi Wang, Eric Fujimura, et al.
Journal of the American Chemical Society|November 10, 2011
Self-assembling small molecules form nanofibrils that bind procaspase-3 to promote activationJulie A Zorn, Holger Wille, Dennis W Wolan, et al.
Science (New York, N.Y.)|November 7, 2009
Small-molecule activators of a proenzymeDennis W Wolan, Julie A Zorn, Daniel C Gray, et al.
The Journal of Biological Chemistry|August 9, 2012
Fibrils colocalize caspase-3 with procaspase-3 to foster maturationJulie A Zorn, Dennis W Wolan, Nicholas J Agard, et al.
Elife|February 21, 2015
Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphateQi Wang, Erik M Vogan, Laura M Nocka, et al.
The Journal of General Virology|March 22, 2007
Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compoundsPuay-Wah Phuan, Julie A Zorn, Jiri Safar, et al.
Journal of Medicinal Chemistry|January 5, 2007
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokineticsBarnaby C H May, Julie A Zorn, Juanita Witkop, et al.
Cancer Immunology Research|August 18, 2022
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with NivolumabKent Thudium, Mark Selby, Julie A Zorn, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Nature Chemical Biology|February 16, 2010
Turning enzymes ON with small moleculesJulie A Zorn, James A Wells
Methods in Enzymology|November 18, 2014
A structural atlas of kinases inhibited by clinically approved drugsQi Wang, Julie A Zorn, John Kuriyan
Plos One|April 4, 2015
Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)Julie A Zorn, Qi Wang, Eric Fujimura, et al.
Journal of the American Chemical Society|November 10, 2011
Self-assembling small molecules form nanofibrils that bind procaspase-3 to promote activationJulie A Zorn, Holger Wille, Dennis W Wolan, et al.
Science (New York, N.Y.)|November 7, 2009
Small-molecule activators of a proenzymeDennis W Wolan, Julie A Zorn, Daniel C Gray, et al.
The Journal of Biological Chemistry|August 9, 2012
Fibrils colocalize caspase-3 with procaspase-3 to foster maturationJulie A Zorn, Dennis W Wolan, Nicholas J Agard, et al.
Elife|February 21, 2015
Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphateQi Wang, Erik M Vogan, Laura M Nocka, et al.
The Journal of General Virology|March 22, 2007
Discriminating between cellular and misfolded prion protein by using affinity to 9-aminoacridine compoundsPuay-Wah Phuan, Julie A Zorn, Jiri Safar, et al.
Journal of Medicinal Chemistry|January 5, 2007
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokineticsBarnaby C H May, Julie A Zorn, Juanita Witkop, et al.
Cancer Immunology Research|August 18, 2022
Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with NivolumabKent Thudium, Mark Selby, Julie A Zorn, et al.
Pageof 2